Phase 1, Multicenter, Open Label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2 Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 30 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Apr 2018 Status changed from not yet recruiting to recruiting.
- 18 Dec 2017 New trial record